In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 213-218

  De Graaff, Michael ^a   Maliepaard, Marc ^a   Pluim, Dick ^a   Floot, Ben J G ^a   Slaper Cortenbach, Ineke C M ^b   Schellens, Jan H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Cellular uptake; CFU GM; Cytotoxic interactions; Platinum drugs; Taxanes

Indexed keywords

CARBOPLATIN; CISPLATIN; CREMOPHOR; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ARTICLE; BONE MARROW CELL; CELL CULTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; GRANULOCYTE; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL;

EID: 0033062781     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00010     Document Type: Article

References (19)

1. Rowinsky EK, Donehouwer RC. Paclitaxel. N Engl J Med 1995; 332: 1004-14.
2. Schellens JHM, Ma J, Planting ASTh, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors. Br J Cancer 1996; 73: 1569-75.
3. Horwitz SB. Mechanism of action of taxol. Trends Pharm Sci 1992; 13: 134-6.
4. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse flbroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
5. Bookman MA, McGuire III WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynaecologic One Group. J Clin Oncol 1996; 14: 1895-902.
6. Huizing MT, van Warmerdam LJ, Rosing H, et al. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997; 15: 1953-64.
7. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of Taxol and cisplatin: a phase I pharmacologic study. J Clin Oncol 1991; 9: 1692-703.
8. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the presence and absence of paclitaxel. Clin Cancer Res 1996; 2: 549-54.
9. Calvert AH. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/ paclitaxel. Semin Oncol 1997; 24 (suppl 2): 85-90.
10. Van Warmerdam LJ, Huizing MT, Giaccone G, et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 1997; 24 (suppl 2): 97-104.
11. Huizing MT, Giaccone G, van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 1997; 15: 317-29.
12. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs or enzyme inhibitors. Adv Enz Reg 1984; 22: 27-55.
13. Chou T-C, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 20: 1517-24.
14. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein using the principles of protein-dye binding. Anal Biochem 1976; 72: 248-54.
15. Ma J, Verweij J, Planting AST, et al. Docetaxel en paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 1996; 37: 382-4.
16. R) in human tumor cell lines. Cancer Chemother Pharmacol 1994; 33: 331-9.
17. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235-42.
18. Planting ASTh, van der Burg MEL, De Boer-Dennert M, Stoter G, Verweij J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumors. Br J Cancer 1993; 68: 789-92.
19. De Vos AI, Nooter K, Verweij J, et al. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol 1997; 8: 1145-50.